Full-Time

Senior Director Biostatistics

Posted on 9/26/2024

Alector

Alector

201-500 employees

Develops therapies for neurodegenerative diseases

Biotechnology
Healthcare

Compensation Overview

$280k - $303kAnnually

Senior

Remote in USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
R
Data Analysis
Requirements
  • Ph.D. in Statistics or related discipline with 10+ years, or MS with 15+ years of proven experience in the biotechnology or related industry, including interaction and submission experiences with both FDA and EMA.
  • Successful project and people management and expertise in the development of Neuroscience and Rare Disease programs.
  • Thorough knowledge of life cycle management; consistent track record of innovatively applying statistical principles, theories, and concepts to clinical drug development leading to regulatory approvals.
  • Deep hands-on operational experiences in Biostatistics deliverables, including study design, protocol development, CRFs, clinical databases, Statistical Analysis Plans (SAP), SDTM/ADaM datasets, and CSR Tables/Figures/Listings.
  • Up to date knowledge of industry and academic developments in the Neuroscience, and apply them to clinical study design and analysis.
  • Demonstrated innovative and flexible ability and mindset to work in a changing and demanding environment. Exercise good judgment in interpreting, modifying, and adapting procedures, practices, methods, etc. in accordance with existing policies and standards.
  • Demonstrated strong leadership, project management, collaboration, communication, and organization skills.
  • Advanced programming skills in SAS, R and other relevant statistical software solutions.
  • Detailed knowledge of adaptive designs, Bayesian methodology, trial simulation, and complex modeling.
  • Innovative problem-solving capabilities, the agility to respond promptly and completely to time-critical tasks.
Responsibilities
  • As the lead Biostatistician for assigned projects and ensure effective, timely and compliant management and delivery of project goals and accountabilities.
  • Define the statistical strategy and ensure appropriate statistical methodologies are applied to study designs and data analyses for clinical trials.
  • Provide expert statistical input and consultancy to Phase I – IV global clinical trials, lifecycle management activities as well as translational medicine research efforts.
  • Ensure a high degree of rigor is applied to the statistical and scientific decision-making process and outcomes.
  • Collaborate with internal and external collaborators in study design, analysis, reporting, interpretation, and communication of clinical trial results.
  • Author and review critical documents such as briefing documents, protocols, SAP, top-line reports, CSR, and integrated summaries.
  • Support the project team and clinical study team including the derivation of go/no-go criteria, summary reports, and results interpretation.
  • Participate in FDA and other regulatory body interactions (IND/CTA filings, safety reporting).

Alector develops therapies aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's. The company focuses on research and development of new drug candidates by utilizing knowledge from immunology, neurology, and human genetics. Their approach involves conducting early-stage clinical trials to gather specific data about diseases, which helps improve the chances of success for their treatments. Alector differentiates itself from competitors by emphasizing the body's natural healing processes in their drug development. The company's goal is to create effective treatments for conditions that currently have limited options, while also attracting funding and partnerships through their research findings.

Company Stage

IPO

Total Funding

$189.2M

Headquarters

San Francisco, California

Founded

2013

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

2%

2 year growth

-11%
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in neuroimmunology boosts investment and collaboration opportunities for Alector.
  • AI-driven drug discovery enhances efficiency, aligning with Alector's technology-driven strategy.
  • Expansion of strategic alliances offers collaboration and resource sharing opportunities for Alector.

What critics are saying

  • Failure in AL002 trial may decrease investor confidence and financial stability.
  • Reliance on external financing increases financial risk if therapies don't succeed commercially.
  • Increased competition in neurodegenerative market could impact Alector's market share.

What makes Alector unique

  • Alector combines antibody technology with neuroimmunology for novel neurodegenerative therapies.
  • Strategic alliance with Adimab enhances Alector's antibody discovery and optimization capabilities.
  • Focus on genetically validated therapies aligns with personalized medicine trends.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE